Crinetics Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.10
Dividend & YieldN/A$ (N/A)
Beta 1.03
Market capitalization 936.3M
Operating cash flow -102.9M
ESG Scores unknown

Company description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 7.36M 696k 2.72M 6.29M
Total Cashflows From Investing Activities -119.46M 41.67M 217k -56.48M
Net Borrowings
Total Cash From Financing Activities 170.2M 67k 114.57M 252.68M
Change To Operating Activities -2.06M -2.83M -2.35M -5.2M
Issuance Of Stock 106.92M 126k 114.57M 252.68M
Net Income -27.11M -50.42M -73.81M -107.64M
Change In Cash 31.28M -4.65M 52.76M 107.61M
Effect Of Exchange Rate
Total Cash From Operating Activities -19.46M -46.38M -62.03M -88.59M
Depreciation 471k 887k 948k 922k
Change To Account Receivables
Other Cashflows From Financing Activities -225k
Change To Netincome 1.89M 5.29M 10.46M 17.04M
Capital Expenditures -1.06M -492k -186k -436k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 24.48M
Income Before Tax -27.11M -50.42M -73.81M -107.64M
Net Income -27.11M -50.42M -73.81M -107.64M
Selling General Administrative 6.66M 13.52M 18.03M 24.52M
Gross Profit -22.05M -40.31M -56.93M -83.18M
Ebit -28.71M -53.83M -74.95M -107.7M
Operating Income -28.71M -53.83M -74.95M -107.7M
Interest Expense
Income Tax Expense
Total Revenue 2.43M 1.19M 71k 1.08M
Cost Of Revenue 24.48M 41.51M 57M 84.25M
Total Other Income ExpenseNet 1.59M 3.41M 1.14M 61k
Net Income From Continuing Ops -27.11M -50.42M -73.81M -107.64M
Net Income Applicable To Common Shares -27.11M -50.42M -73.81M -107.64M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 11.19M 13.24M 14.53M 19.07M
Total Stockholder Equity 160.22M 117.14M 168.92M 331.94M
Other Current Liabilities 381k
Total Assets 171.41M 130.38M 183.44M 351.01M
Common Stock 203.54M 210.79M 336.51M 607.58M
Other Current Assets 8k 2.48M 3.06M 7.74M
Retained Earnings -43.38M -93.8M -167.61M -275.25M
Treasury Stock 61k 148k 25k -382k
Cash 44.97M 40.33M 93.09M 200.69M
Total Current Liabilities 7.92M 8.34M 10.49M 15.99M
Other Stockholder Equity 61k 148k 25k -382k
Property, Plant, and Equipment 4.23M 6.46M 5.41M 4.72M
Total Current Assets 166.68M 123.34M 177.49M 344.72M
Net Tangible Assets 160.22M 117.14M 168.92M 331.94M
Net Receivables 1.92M 1.15M 1.83M 1.48M
Accounts Payable 1.67M 2.7M 3.49M 4.27M


Insider Transactions

Here are the insider transactions of stock shares related to Crinetics Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BETZ STEPHEN FSale at price 18.72 per share.D2022-11-15Officer3.13k
BETZ STEPHEN FSale at price 18.52 per share.D2022-11-01Officer3.13k
BETZ STEPHEN FSale at price 17.73 per share.D2022-10-17Officer3.13k
STRUTHERS RICHARD SCOTTConversion of Exercise of derivative security at price 1.91 per share.D2022-10-12Chief Executive Officer11.1k
PIZZUTI DANAStock Award(Grant) at price 0.00 per share.D2022-10-10Officer12.5k
BETZ STEPHEN FSale at price 19.64 per share.D2022-10-03Officer3.13k
BETZ STEPHEN FSale at price 21.01 per share.D2022-09-15Officer4.17k
BETZ STEPHEN FSale at price 21.00 per share.D2022-09-07Officer1.04k
BETZ STEPHEN FSale at price 18.59 per share.D2022-09-01Officer3.13k
KNIGHT JEFF ESale at price 20.70 per share.D2022-07-26Chief Operating Officer1.15k
FUST MATTHEW K.Sale at price 20.96 per share.D2022-07-13Director5.7k
FUST MATTHEW K.Conversion of Exercise of derivative security at price 1.45 per share.D2022-07-13Director5.7k
BETZ STEPHEN FSale at price 20.10 per share.D2022-05-02Officer3.25k
PERCEPTIVE ADVISORS, L.L.C.Purchase at price 22.22 per share.I2022-04-18Beneficial Owner of more than 10% of a Class of Security157.51k
BETZ STEPHEN FSale at price 25.81 per share.D2022-04-18Officer5.66k
STRUTHERS RICHARD SCOTTSale at price 25.42 - 27.53 per share.I2022-04-13Chief Executive Officer138.64k
STRUTHERS RICHARD SCOTTSale at price 25.34 per share.I2022-04-05Chief Executive Officer21.36k
BETZ STEPHEN FSale at price 23.97 per share.D2022-04-04Officer9k
BETZ STEPHEN FSale at price 21.06 - 21.80 per share.D2022-04-01Officer8.33k
BETZ STEPHEN FSale at price 18.94 per share.D2022-03-15Officer3.12k
MADAN AJAYSale at price 19.88 per share.D2022-03-01Officer9k
BETZ STEPHEN FSale at price 19.73 per share.D2022-03-01Officer3.12k
KRASNER ALAN SETHStock Award(Grant) at price 0.00 per share.D2022-02-28Officer14.25k
STRUTHERS RICHARD SCOTTStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Executive Officer53.4k
WILSON MARCStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer19.5k
MADAN AJAYStock Award(Grant) at price 0.00 per share.D2022-02-28Officer13.95k
KNIGHT JEFF EStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Operating Officer4.95k
BETZ STEPHEN FStock Award(Grant) at price 0.00 per share.D2022-02-28Officer16.5k
BETZ STEPHEN FSale at price 18.64 per share.D2022-02-15Officer3.12k
MADAN AJAYSale at price 17.83 per share.D2022-02-07Officer13.41k
BETZ STEPHEN FSale at price 18.79 per share.D2022-02-01Officer3.12k
KRASNER ALAN SETHSale at price 21.21 per share.D2022-01-19Officer6.7k
KRASNER ALAN SETHConversion of Exercise of derivative security at price 12.01 per share.D2022-01-19Officer6.7k
BETZ STEPHEN FSale at price 23.29 per share.D2022-01-18Officer4.17k
BETZ STEPHEN FSale at price 28.02 per share.D2022-01-03Officer7.17k
BETZ STEPHEN FSale at price 27.95 per share.D2021-12-28Officer3k
BETZ STEPHEN FSale at price 24.14 per share.D2021-12-15Officer5.67k
BETZ STEPHEN FSale at price 27.38 per share.D2021-12-01Officer5.67k
BETZ STEPHEN FSale at price 26.75 - 27.97 per share.D2021-11-16Officer7.17k
BETZ STEPHEN FSale at price 27.95 - 28.42 per share.D2021-11-08Officer16.5k
FUST MATTHEW K.Sale at price 25.50 per share.D2021-11-01Director8.95k
FUST MATTHEW K.Conversion of Exercise of derivative security at price 1.91 per share.D2021-11-01Director8.95k
BETZ STEPHEN FSale at price 24.79 per share.D2021-11-01Officer5.67k
MADAN AJAYConversion of Exercise of derivative security at price 0.73 per share.D2021-10-28Officer106.38k
BETZ STEPHEN FSale at price 24.00 per share.D2021-10-27Officer3k
PERCEPTIVE ADVISORS, L.L.C.Purchase at price 19.80 per share.I2021-10-25Beneficial Owner of more than 10% of a Class of Security1.2M
BETZ STEPHEN FSale at price 21.10 per share.D2021-10-21Officer1.04k
FUST MATTHEW K.Sale at price 25.50 per share.D2021-09-08Director6.05k
FUST MATTHEW K.Conversion of Exercise of derivative security at price 1.91 per share.D2021-09-08Director6.05k
STRUTHERS RICHARD SCOTTSale at price 25.00 per share.I2021-09-07Chief Executive Officer30k
FUST MATTHEW K.Sale at price 19.59 per share.D2021-07-26Director5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Crinetics Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Crinetics Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Crinetics Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Crinetics Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 27.93% on the backtest period.

Performance at glance

Performance

27.93 %

Latent gain

422.59 $

Invested capital

1512.77 $

Annualized return

8.03 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Crinetics Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Crinetics Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Crinetics Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 54.11% of return on Crinetics Pharmaceuticals Inc. That represents 2717.97$ of latent gain with 5023.47$ of employed capital.
  • The second momentum investment strategy would give 55.41% of return on Crinetics Pharmaceuticals Inc. That represents 2098.75$ of latent gain with 3787.97$ of employed capital.
Performance at glance (1Q Momentum)

Performance

54.11 %

Latent gain

2717.97 $

Invested capital

5023.47 $

Annualized return

18.92 %
Performance at glance (2Q Momentum)

Performance

55.41 %

Latent gain

2098.75 $

Invested capital

3787.97 $

Annualized return

18.47 %

Momentum equity curve on Crinetics Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Crinetics Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Crinetics Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Crinetics Pharmaceuticals Inc since the beginning:

Crinetics Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Crinetics Pharmaceuticals Inc

Buy the dip entry openings on Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

The performance achieved by the robo-advisor on Crinetics Pharmaceuticals Inc is 28.0%. That represents 70.56$ of latent gain with 252.0$ of employed capital. The following chart shows Crinetics Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Crinetics Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

28.0 %

Latent gain

70.56 $

Invested capital

252.0 $

Annualized return

18.92 %

Equity curve of the strategy applied to Crinetics Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals Inc

Note: the dividends potentially given by Crinetics Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Crinetics Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Crinetics Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Crinetics Pharmaceuticals Inc.

Equity curve comparison on Crinetics Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Crinetics Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc investment comparison

Performance comparison on Crinetics Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 27.93% 422.59$ 1512.77$ 8.03%
Momentum 1 quarter 54.11% 2717.97$ 5023.47$ 16.7%
Momentum 2 quarters 55.41% 2098.75$ 3787.97$ 18.47%
Non-directional 28.0% 70.56$ 252.0$ 18.92%
Annualized return comparison

Automatic investment

8.03 %

Momentum 1Q

18.47 %

Momentum 2Q

18.47 %

Non-directional

18.92 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Crinetics Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Crinetics Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • Acer Therapeutics Inc
  • EVOLVE ACTIVE CDN PREF SHARE FUND
  • Crinetics Pharmaceuticals Inc
  • ALITHYA GROUP INC

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Crinetics Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Crinetics Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Crinetics Pharmaceuticals Inc
    Country United States
    City San Diego
    Address Building No. 2
    Phone 858 450 6464
    Website www.crinetics.com
    FullTime employees 143
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker CRNX
    Market www.nasdaq.com

    Crinetics Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown